Cardiac adiposity: Epicardial and pericardial fat, atherosclerosis, insulin resistance, and other partners in crime

Handbook on Metabolic Syndrome: Classification, Risk Factors and Health Impact

Volumn , Issue , 2012, Pages 145-167

  Lima Martínez, Marcos M ^a,b,e   Aguirre, Miguel ^a,c   Rojas, Joselyn ^a,c   Paoli, Mariela ^a   Iacobellis, Gianluca ^d  

^a Hospital Universitario de Los Andes   (Venezuela)

^b Universidad de Oriente Nucleo Bolivar   (Venezuela)

^c UNIVERSIDAD DEL ZULIA   (Venezuela)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Miller School of Medicine ^*  (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896193813     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (163)

1. Marchington JM, Mattacks CA, Pond CM. Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties. Comparative Biochem. Physiol. 1989;94B:225-32.
2. Pond CM, Mattacks CA, Calder PC, Evans J. Site-specific properties of human adipose depots homologous to those of other mammals. Comparative Biochem. Physiol. 1993;104A:819-24.
3. Reiner L, Mazzoneli A, Rodríguez FL. Statistical analysis of the epicardial fat weight in human hearts. AMA Arch. Pathol. 1955;60:369-73.
4. Nakazato R, Dey D, Cheng VY, Gransar H, Slomka PJ, Hayes SW, Thompson LEJ, Friedman JD, Min JK, Berman DS. Epicardial fat volume and concurrent presence of both myocardial ischemia and obstructive coronary artery disease. Atherosclerosis 2012 Doi: http:// dx.doi.org/10.1016/j.atherosclerosis.2011.12.018.
5. Huang G, Wang D, Zeb I, Budoff MJ, Harman SM, Miller V, Brinton EA, El Khoudary SR, Manson JE, Sowers MR, Hodis HN, Merriam GR, Cedars MI, Taylor HS, Naftolin F, Lobo RA, Santoro N, Wildman RP. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis 2011 Doi: http://dx.doi.org/10.1016/j.atherosclerosis. 2011.12.004.
6. Yerramasu A, Dey D, Venuraju S, Anand DV, Atwal S, Corder R, Berman DS, Lahiri A. Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis 2012;220:223-30.
7. Ito T, Nasu K, Terashima M, Ehara M, Kinoshita Y, Ito T, Kimura M, Tanaka N, Habara M, Tsuchikane E, Suzuki T. The impact of epicardial fat volume on coronary plaque vulnerability: insight form optical coherence tomography analysis. Eur. Heart J. Cardiovasc. Imaging 2012 Doi: doi: 10.1093/ehjci/jes022.
8. Doesch C, Haghi D, Fluchter S, Suselbeck T, Schoenberg SO, Michaely H, Borggrefe M, Papavassiliu T. Epicardial adipose tissue in patients with heart failure. J. Cardiovasc. Magnetic Resonance 2010;12:40.
9. Lima-Martínez MM, Iacobelis G. Grasa epicardica: una nueva herramienta para la evaluación del riesgo cardiometabólico. Hipertens. riesgo. vasc. 2011;28:63-8.
10. Yorgun H, Canpolat U, Hazirolan T, Ates AH, Sunman H, Dural M, Sahiner L, Kaya EB, Aytemir K, Tokgozoglu L, Kabakçi G, Oto A. Increased epicardial fat tissue is a marker of metabolic syndrome in adult patients. Int. J. Cardiol. 2011 http://dx.doi.org/10.1016/j.ijcard. 2011.08.067.
11. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R, et al. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-96.
12. Fox CS, Massaro JM, Hoffmann U, Pon KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr, O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116: 39-48.
13. Iacobellis G. Obesity and cardiovascular disease. 1a ed. UK: Oxford University Press; 2009.
14. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomical, biomolecular and clinical relation to the heart. Nat. Cardiovasc. Clin. Pract. Med. 2005; 2: 536-43.
15. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O'Donnell CJ, Fox CS, Hoffmann U. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: The Framingham Heart Study. Eur. Heart J. 2009;30:850-6.
16. Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, Massaro JM, Levy D, Larson MG, D'Agostino RB Sr, O'Donnell CJ, Manning WJ. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: The Framingham Heart Study. Circulation 2009; 119:1586-91.
17. Sadler TW. Langman's Medical embryology. 10th edition. Lippincott Williams and wilkins, 2006. P165-168.
18. Gollasch M, Dubrovska G. Paracrine role for periadventitial adipose tissue in the regulation of arterial tone. Trends Pharmacol. Sci. 2004;25: 647-53.
19. Gao YJ. Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular dysfunction. Curr. Pharm. Des. 2007;13:2185-92.
20. Rabkin SW. Epicardial fat: properties, function and relationship to obesity. Obes. Rev. 2007; 8:253-61.
21. Marchington JM, Pond CM. Site specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high - fat feeding on lipogenesis and the incorporation of fatty acids in vivo. Int. J. Obesity 1990; 14: 1013-22.
22. Iatropoulos M, Williams G. The function and pathology of brown adipose tissue in animals and humans. J. toxicol. Pathol. 2004; 17: 147-53.
23. Poissonnet CM, Burdi AR, Garn SM. The chronology of adipose tissue appearance and distribution in the human fetus. Early Human Development 1984;10:1-11.
24. Poissonnet CM, Burdi AR, Bookstein FL. Growth and development of human adipose tissue during early gestation. Early Human Development 1983;8:1-11.
25. Trayhurn P. Brown adipose tissue: from thermal physiology to bioenergetics. J. Biosciences 1993;18:161-73.
26. Richard D, Picard F. Brown fat biology and thermogenesis. Frontiers Bioscience 2011; 16:1233-60.
27. Azzu V, Brand MD. The on-off switches of the mitochondrial uncoupling proteins. Trends Biochem. Sci. 2010;35:298-307.
28. Collins S, Yehuda-Shnaidman E, Wang H. Positive and negative control of Ucp1 gene transcription and the role of ?-adrenergic signaling networks. Int. J. Obes. 2010;34 Suppl 1:S28-33.
29. Cao W, Daniel KW, Robidoux J, Puigserver P, Medvedev AV, Bai X, Floering LM, Spiegelman BM, Collins S. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol. Cell Biol. 2004; 24: 3057-67.
30. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessí-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J. Clin. Invest. 2012 Doi: 10.1172/JCI59701.
31. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol. Metab. 2008;19: 130-7.
32. Nishikimi T, Iemura-Inaba C, Akimoto K, Ishikawa K, Koshikawa S, Matsuoka H. Stimulatory and inhibitory regulation of lipolysis by the NPR-A/cGMP/PKG and NPRC/ Gi pathways in rat cultured adipocytes. Regulatory Peptides 2009;153:56-63.
33. Peseshkian M, Noori M, Najjarour-Jabbari H, Abolfathi A, Darabi M, Darabi M, Shaaker M, Shahmohammdi G. Fatty acid composition of epicardial and subcutaneous human adipose tissue. Metab. Syndr. Relat. Disord. 2009;7:125-32.
34. Rabkin SW. Epicardial fat: properties, function and relationship to obesity. Obes. Rev. 2007; 8: 253-61.
35. Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid binding proteins. Cell Mol. Life Sci 2002;59:1096-1116.
36. Fain JN, Sacks HS, Bahouth SW, Tichansky DS, Madan AK, Cheema PS. Human epicardial adipokine messenger RNAs: comparisons of their expression in substernal, subcutaneous, and omental fat. Metabolism 2010;59:1379-86.
37. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 2006;290: E1253-61.
38. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Rea JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity 2011; 19:1552-9.
39. Iacobellis G, di Goia CR, Cotesta D, Petramala L, Travaglini C, De Santis V, Vitale D, Tritapepe L, Letizia C. Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Horm. Metab. Res. 2009;41:227-31.
40. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003;26:2442-50.
41. Lima MM, Rosa FJ, Marin A, Romero-Vecchione E. Adiponectina y sus efectos pleiotrópicos en el sistema cardiovascular. Rev. Venez. Endocrinol. Metab. 2009;7:3-9.
42. Rojas J, Arraiz N, Aguirre M, Velasco M, Bermúdez V. AMPK as target for intervention in childhood and adolescent obesity. J. Obes. 2010; 2011: 252817 Doi: 10.1155/2011/252817.
43. Tishinsky JM, Robinson LE, Dyck DJ. Insulin-sensitizing properties of adiponectin. Biochimie 2012 Doi: http://dx.doi.org/10.1016/j.biochi. 2012.01.017.
44. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
45. Schulze MB, Shai I, Rimm EB, Li t, Rifai n, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534-9.
46. Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G, Gallo P, di Gioia CR. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 2005; 29: 251-5.
47. Wolfson N, Gavish D, Matas Z, Boaz M, Shargorodsky M. Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load. Exp. Diabetes Res. 2012;2012:250621 Doi: 10.1155/ 2012/ 250621.
48. Silaghi A, Achard V, Paulmyer-Lacroix O, Scridon T, Tassistro V, Duncea I, Clément K, Dutour A, Grino M. Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status. Am. J. Physiol. Endocrinol. Metab. 2007;293:E1443-50.
49. Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol. Ther. 2006; 111: 909-27.
50. Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJV. The clinical relevance of adrenomedullin: a promising profile?. Pharmacol. Ther. 2004;103:179-201.
51. Shinomiya K, Ohmori K, Ohyama H, Hosomi N, Takahashi T, Osaka K. Association of plasma adrenomedullin with carotid atherosclerosis in chronic ischemic stroke. Peptides 2001;22:1873-80.
52. Savoia C, Schiffrin EL. Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin. Med. Clin. N. Am. 2004; 88: 39-62.
53. Jougasaki M, Grantham JA, Redfield RR, Burnett Jr. JC. Regulation of cardiac adrenomedullin in heart failure. Peptides 2001;22:1841-50.
54. Hayashi M, Shimosawa T, Isaka M, Yamada S, Fujita R, Fujita T. Plasma adrenomedullin in diabetes. Lancet 1997;350:1449-50.
55. Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 1998;31:505-10.
56. Cases A, Esforzado N, Vera M, Lario S, López-Pedret J, Jiménez W, Rivera-Fillat F. Niveles elevados de adrenomedulina en pacientes hipertensos en programa de hemodiálsis. Nefrologia 2000;20:424-30.
57. Iacobellis G, di Goia CR, Di Vito M, Petramala L, Cotesta D, De Santis V, et al. Epicardial adipose tissue and intracoronary adrenomedullin levels in coronary artery disease. Horm. Metab. Res. 2009;41:855-60.
58. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ. Res. 2009;104:541-9.
59. Guzik TJ, Marvar PJ, Czesnikiewicz-Guzik M, Korbut R. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J. Physiol. Pharmacol. 2007;58:591-610.
60. Takemori K, Gao YJ, Ding L, Lu C, Su LY, An WS, Vinson C, Lee RM. Elevated blood pressure in transgenic lipoatrophic mice and altered vascular function. Hypertension 2007;49:365-72.
61. Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J. 2002;16:1057-63.
62. Sahin AS, Bariskaner H. The mechanisms of vasorelaxant effect of leptin on isolated rabbit aorta. Fundam. Clin. Pharmacol. 2007;21:595-600.
63. Beltowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin. Ex. Pharmacol. Physiol. 2012;39:168-78.
64. Gil-Ortega M, Stucchi P, Guzmán-Ruiz R, Cano V, Arribas S, González MC, Ruiz- Gayo M, Fernández-Alfonso MS, Somoza B. Adaptative nitric oxide overproduction in perivascular adipose tissue during early diet-induced obesity. Endocrinology 2010; 151: 3299-3306.
65. Fésus G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft F, Gollasch M. Adiponectin is a novel humoral vasodilator. Cardiovasc. Res. 2007;75:719-27.
66. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30: 535-41.
67. Barlow RS, White RE. Hydrogen peroxide relaxes porcine coronary arteries by stimulating BKCa channel activity. Am. J. Physiol. 1998;275: H1283-H1289.
68. Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol 1996;271:H1262-H1266.
69. Gao YJ, Hirota S, Zhang D, Janssen LJ, Lee RMKW. Mechanisms of hydrogen peroxide-induced biphasic response in rat mesenteric artery. Br. J. Pharmacol. 2003; 138: 1085-1092.
70. Yudkin JS, Eringa E, Stehouwer CDA. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817-20.
71. Maenhaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Medicine 2011;9:25.
72. Houben AJ, Eringa EC, Jonk AM, Serne EH, Smulders YM, Stehouwer CD. Perivascular fat and microcirculation: relevance to insulin resistance, diabetes, and cardiovascular disease. Curr. Cardiovasc. Risk Rep. 2012;6:80-90.
73. Chaldakov GN. Cardiovascular adipobiology: a novel heart-associated adipose tissue in cardiovascular disease. Ser. J. Exp. Clin. Res. 2008; 9:81-8.
74. Rajsheker S, Manka D, Blomkalns AL, Chatterjee TK, Stoll LL, Weintraub NL. Crosstalk between perivascular adipose tissue and blood vessels. Curr. Opin. Pharmacol. 2010;10:191-6.
75. Cooney MT, Dubina AL, Graham IN. Value and limitations of existing scores for the assessment of cardiovascular risk. J. Am. Coll. Cardiol. 2009; 54:1209-27.
76. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011;17:1410-22.
77. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460-6.
78. Greif M, Becker A, von Ziegler F, Lebherz C, Lehrke M, Broedl UC, Tittus J, Parhofer K, Becker C, Reiser M, Knez A, Leber AW. Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009;29: 781-6.
79. Medzhitov R, Janeway Jr CA. An ancient system of host defense. Curr. Opin. Immunol. 1998; 10:12-5.
80. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 2002; 1589:1-13.
81. Muzio M, Polentarrutti N, Bosisio D, Manoj Kumar PP, Mantovani A. Toll-like receptor family and signalling pathway. Biochem. Soc. Trans. 2000; 28: 563-6.
82. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2007; 292: E740-7.
83. Baker AR, Harte AL, Howell N, Pritlove C, Ranasinghe AM, Da Silva NF, Youssef EM, Khunti K, Davies MJ, Bonser RS, Kumar S, Pagano D, McTernan PG. Epicardial adipose tissue as a source of nuclear factor- kappa B and c-jun N-terminal kinase mediated inflammation in patients with coronary artery disease. J. Clin. Endocrinol. Metab. 2009;94:261-7.
84. Eiras S, Teijeira-Fernández E, Salgado-Somoza A, Couso E, García-Caballero T, Sierra J, Juanatey JR. Relationship between epicardial adipose tissue adipocyte size and MCP- 1 expression. Cytokine 2010; 51: 207-12.
85. Bambace C, Telesca M, Zoico E, Sepe A, Olioso D, Rossi A, Corzato F, Di Francesco V, Mazzucco A, Santini F, Zamboni M. Adiponectin gene expression and adipocyte diameter: a comparison between epicardial and subcutaneous adipose tissue in men. Cardiovasc. Pathol. 2011; 20: e153-6.
86. Van Gaal LF, Mertens IL, De Block CE. Mechanism linking obesity with cardiovascular disease. Nature 2006; 444: 875-80.
87. Boyanovsky BB, Webb NR. Biology of secretory phospholipase A2. Cardiovasc. Drugs Ther. 2009;23:61-72.
88. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther. 2009;23:93-101.
89. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2) modifications of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J. Biol. Chem. 1999;274:25913-20.
90. Sartipy P, Johansen B, Gâsvik K, Hurt-Camejo E. Molecular basis for the association of group II A phospholipase A(2) and decorin in human atherosclerotic lesions. Circ. Res. 2000; 86:707-14.
91. Hakala JK, Oörni K, Pentikäinen MO, Hurt-Camejo E, Kovanen PT. Lypolisis of LDL by human secretory phospholipase A(2) induces particle fusión and enhances the retention of LDL to human aortic proteoglycans. Arterioscler. Thomb. Vasc. Biol. 2001; 21: 1053-8.
92. Dutour A, Achard V, Sell H, Naour N, Collart F, Gaborit B, Silaghi A, Eckel J, Alessi MC, Henegar C, Clément K. Secretory type II phospholipase A2 is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease. J. Clin. Endocrinol. Metab. 2010;95:963-7.
93. Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian M, Navab M, Fogelman AM, Grass DS, Swanson ME, de Beer MC, de Beer F, Lusis AJ. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 1999;19:1284-90.
94. Menschikowski M, Rosner-Schiering A, Eckey R, Mueller E, Koch R, Jaross W. Expression of secretory group IIA phospholipase A(2) in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. Arterioscler. Thromb. Vasc. Biol. 2000;20:751-62.
95. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280-4.
96. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie T, Otterdal K, Gullestad L, Damas JK. Chemokines and cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 2008;28: 1909-19.
97. Karastergiou K, Evans I, Ogston N, Miheisi N, Nair D, Kaski JC, Jahangiri M, Mohamed-Ali V. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2010;30:1340-6.
98. Salgado-Somoza A, Teijeira-Fernández E, Fernández AL, González-Juanetey JR, Eiras S. Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 2010; 299: H202-9.
99. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Aterioscler. Thromb. Vasc. Biol. 2005;25:29-38.
100. Yoshizumi M, Abe JI, Haendeler J, Huang Q, Berk BC. Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species. J. Biol. Chem. 2000; 275:11706-12.
101. Henrichot E, Juge-Aubry CE, Pernin A, Pache JC, Velebit V, Dayer JM, Meda P, Chizzolini C, Meier CA. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis?. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2594-9.
102. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, Lee RMKW. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc. Res. 2006;71:363-73.
103. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest. 2002;109:817-26.
104. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007;87:315-424.
105. Gustafsson F, Holstein-Rathlou NH. Angiotensin II modulates conducted vasoconstriction to norepinephrine and local electrical stimulation in rat mesenteric arterioles. Cardiovasc. Res. 1999;44:176-84.
106. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994;74:1141-8.
107. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II-induces hypertension and vascular dysfunction. J. Exp. Med. 2007;204:2449-60.
108. Umemura M, Kawabe T, Shudo K, Kidoya H, Fukui M, Asano M, Iwakura Y, Matsuzaki G, Imamura R, Suda T. Involvement of IL-17 in Fas ligand-induced inflammation. Int. Immunol. 2004;16:1099-108.
109. Ishizaka N, Aizawa T, Ohno M, Usui Si S, Mori I, Tang SS, Ingelfinger JR, Kimura S, Nagai R. Regulation and localization of HSP70 and HSP25 in the kidney of rats undergoing long-term administration of angiotensin II. Hypertension 2002;39:122-8.
110. Leng X, Zhan R, Wang Y, Liu X, Gong J, Gao X, Wu L, Wang L, Zhao Y, Wang X, Zhang Z, Pang W, Qian L. Anti-heat shock protein 70 autoantibody epitope changes and BD091 promotes atherosclerosis in rats. Cell Stress Chaperones 2010;15:947-58.
111. Ghayour-Mobarhan M, Lamb DJ, Tavallaie S, Ferns GA. Relationship between plasma cholesterol, von Willebrand factor concentrations, extent of atherosclerosis and antibody titres to heat shock proteins-60, -65 and -70 in cholesterol-fed rabbits. Int. J. Exp. Pathol. 2007; 88: 249-55.
112. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clin. Sci. 2005;109:243-56.
113. Chen C, Jiang J, Lu JM, Chai H Wang X, Lin PH, Yao Q. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2010;299:H193-201.
114. Shyu KG, Lien LM, Wang BW, Kuan P, Chang H. Resistin contributes to neointimal formation via oxidative stress after vascular injury. Clin. Sci. 2011;120:121-9.
115. Cho Y, Lee SE, Lee HC, Hur J, Lee S, Youn SW, Lee J, Lee HJ, Lee TK, Park J, Hwang SJ, Kwon YW, Cho HJ, Oh BH, Park YB, Kim HS. Adipokine resistin is a key player to modulate mobocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J. Am. Coll. Cardiol. 2011; 57: 99-109.
116. Choi HY, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Association of adiponectin, resistin, and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Arterioscler. Thromb. Vasc. Biol. 2011;31:944-9.
117. Langheim S, Dreas L, Veschini L, Maisano F, Foglieni C, Ferrarello S, Sinagra G, Zingone B, Alfieri O, Ferrero E, Maseri A, Ruotolo G. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. Am. J. Physiol. Heart Circ. Physiol. 2010;298:H746-53.
118. Fukuhara A, Matsuda M, Mishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi , Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
119. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B cell colony-enhancing factor. Mol. Cell Biol. 1994;14:1431-7.
120. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem. Biophys. Res. Commun. 2009;383:503-8.
121. Vallejo S, Romacho T, Angulo J, Villalobos LA, Cercas E, Leivas A, Bermejo E, Carraro R, Sánchez-Ferrer CF, Peiró C. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS ONE 2011;6:e27299.
122. Terra X, Auguet T, Quesada I, Aguilar C, Luna AM, Hernández M, Sabench F, Porras JA, Martínez S, Lucas A, Pellitero S, Llutart J, Del Castillo D, Richart C. Increased levels of adipose tissue expression of visfatin inmorbidly obese women. The relationship with pro-inflammatory cytokines. Clin. Endocrinol. 2011 Doi: 10.1111/ j.1365-2265. 2011.04327.
123. Friebe D, Neef M. Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T, Stumvoll M, Blüher M, Kiess W, Körner A. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011; 54: 1200-11.
124. Tune JD, Considine RV. Effect of leptin on cardiovascular physiology. J. Am. Soc. Hypertens. 2007;1:231-41.
125. Busch HJ, Schirmer SH, Jost M, van Stijn S, Peters SL, Piek JJ, Bode C, Buschmann IR, Mies G. Leptin augments cerebral hemodynamic reserve after three-vessel occlusion: distinct effects on cerebrovascular tone and proliferation in a nonlethal model of hypoperfused rat brain. J. Cereb. Blood Flow Metab. 2011;31:1085-92.
126. Biasucci LM, Graziani F, Rizzello V, Liuzzo G, Guidone C, De Caterina AR, Brugaletta S, Mingrone G, Crea F. Paradoxical preservation of vascular function in severe obesity. Am. J. Med. 2010;123:727-34.
127. Leung YM, Kwan CY. Dual vascular effects of leptin via endothelium: hypothesis and perspective. Chin. J. Physiol. 2008;51:1-6.
128. Hideyuki Y. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol. Pharm. Bull. 2011;34: 307-10.
129. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brezillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 2003;198:977-985.
130. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, Zhang X, Wang L, Tao H. Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc. Diabetol. 2011; 10:87.
131. Yoo HJ, Choi HY, Yang SJ, Kim HY, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH. Circulating chemerin level is independently correlated with arterial stiffness. J. Atheroscler. Thromb. 2012;19:59-68.
132. Dong B, Ji W, Zhang Y. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern. Med. 2011;50:1093-7.
133. Ernst MC, Haidl ID, Zúñiga LA, Dranse HJ, Rourke JL, Zabel BA, Butcher EC, Sinal CJ. Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology 2012;153:672-82.
134. Shin HY, Lee DC, Chu SH, Jeon JY, Lee MK, Im JA, Lee JW. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin. Endocrinol. 2011 Doi: 10.1111/j.1365-2265.2011. 04217.x.
135. HIda K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourau S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. USA 2005; 102:10610-15.
136. Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL, Park JY. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 2011; 413: 264-9.
137. Aust G, Richter O, Rohm S, Kerner C, Hauss J, Klöting N, Ruschke K, Kovacs P, Youn BS, Blüher M. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009;204:262-6.
138. Li HL, Peng WH, Cui ST, Lei H, Wei YD, Li WM, Xu YW. Vaspin plasma concentrations and mRNA expressions inpatients with stable and unstable angina pectoris. Clin. Chem. Lab. Med. 2011;49:1547-54.
139. Phalitakul S, Okada M, Hara Y, Yamawaki H. Vaspin prevents TNF-?-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF- ?B and PKC? activation in cultured rat vascular smooth muscle cells. Pharmacol. Res. 2011; 64:493-500.
140. Könczöl K, Pintér O, Ferenczi S, Varga J, Kovács K, Palkovits M, Zelena D, Tóth ZE. Nesfatin-1 exerts long-term effect on food intake and body temperature. Int. J. Obes. 2012 Doi: 10.1038/ijo.2012.2.
141. Riva M, Nitert MD, Voss U, Sathanoori R, Lindgvist A, Ling C, Wierup N. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res. 2011;346:393-405.
142. Yamawaki H, Takahashi M, Mudohda M, Morita T, Okada M, Hara Y. A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem. Biophys. Res. Commun. 2012 Doi: http://dx.doi.org/10.1016/j.bbrc. 2012.01.076.
143. Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br. J. Pharmacol. 2012;165:643-58.
144. Lamers D, Schlich R, Greulich S, Sasson S, Sell H, Eckel J. Oleic acid and adipokines synergize in inducing proliferation and inflammatory signalling in human vascular smooth muscle cells. J. Cell Mol. Med. 2011; 15:1177-88.
145. Barandier C, Montani JP, Yang Z. Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity. Am. J. Physiol. Heart Circ. Physiol. 2005; 289: H1807-H1813.
146. Motobayashi Y, Izawa-Ishizawa Y, Ishizawa K, Orino S, Yamaguchi K, Kawazoe K, Hamano S, Tsuchiya K, Tomita S, Tamaki T. Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase activation, but not Akt in vascular smooth muscle cells. Hypertens Res. 2009; 32:188-93.
147. Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, Touyz RM. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension 2011;58:479-88.
148. Herrmann J, Lerman LO, Rodriguez-Porcel M, Holmes DR Jr, Richardson DM, Ritman EL, Lerman A. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc. Res. 2001; 51:762-6.
149. Gössl M, Herrmann J, Tang H, Versari D, Galili O, Mannheim D, Rajkumar SV, Lerman LO, Lerman A. Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. Basic Res. Cardiol. 2009; 104:695-706.
150. Madonna R, De Caterina R. Atherogenesis and diabetes: focus on insulin resistance and hyperinsulinemia. Rev. Esp. Cardiol. 2012 Doi: 10.1016/ j.recesp.2011.11.010.
151. Rojas J, Bermúdez V, Leal E, Cano R, Luti Y, Acosta L, Finol F, Aparicio D, Arraiz N, Linares S, Rojas E, Canelón R, Sánchez D. Insulinorresistencia e hiperinsulinemia como factores de riesgo para enfermedad cardiovascular. AVFT 2008;27:29-39.
152. Galli-Tsinopoulou A, Kyrgios I, Maggana I, Giannopoulou EZ, Kotanidou EP, Stylianou C, Papadakis E, Korantzis I, Varlamis G. Insulin resistance is associated with at least threefold increased risk for prothrombosic state in severely obese youngsters. Eur. J. Pediatr. 2011; 170: 879-86.
153. Monte SV, Caruana JA, Ghanim H, Sia CL, Korzeniewski K, Schentag JJ, Dandona P. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery 2011 http://dx.doi.org/10.1016/j.surg.2011.09.038.
154. Bonsignore MR, Esquinas C, Barceló A, Sanchez-de-la-Torre M, Paternó A, Duran- Cantolla J, Marín JM, Barbé F. Metabolic syndrome, insulin resistance and sleepiness in real-life obstructive sleep apnoea. Eur. Respir. J. 2011 Doi: 10.1183/09031936. 00151110.
155. Takaoka M, Nagata D, Kihara S, Shimomura I, Kimura Y, Tabata Y, Saito Y, Nagai R, Sata M. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ. Res. 2009;105:906-11.
156. Rittig K, Staib K, Machann J, Böttcher M, Peter A, Schick F, Claussen C, Stefan N, Fritsche A, Häring HU, Balletshofer B. Perivascular fatty tissue at the brachial artery is linked to insulin resistance but not to local endothelial dysfunction. Diabetologia 2009;51:2093-99.
157. Rittig K, Dolderer JH, Balletshofer B, Machann J, Schick F, Meile T, Küper M, Stock UA, Staiger H, Machicao F, Schaller HE, Königsrainer A, Häring HU, Siegel-Axel DI. The secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells. Diabetologia 2012 Doi: 10.1007/s00125-012-2481-9.
158. Cicha I, Wörner A, Urschel K, Beronov K, Goppelt-Struebe M, Verhoeven E, Daniel WG, Garlichs CD. Carotid plaque vulnerability: a positive feedback between hemodynamic and biochemical mechanisms. Stroke 2011;42:3502-10.
159. Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology 2008;15:79-89.
160. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-904.
161. Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serné EH, Smulders YM, Stehouwer CD. Meal-related increases in microvascular vasomotion are impaired in obese individuals: a potential mechanism in the pathogenesis of obesity-related insulin resistance. Diabetes Care 2011;34 Suppl 2:S342-8.
162. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment?. Circulation 2001;104:735-40.
163. Maiellaro K, Taylor WR. The role of the adventitia in vascular inflammation. Cardiovasc. Res. 2007;75:640-8.